Option Care Health Projects Strong Revenue Growth for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 Jan 26
Source: Business Insider
Option Care Health's stock rose by 9.14% as it crossed above the 5-day SMA, reflecting positive market response to its financial projections.
The company reported anticipated net revenue for 2026 to reach between $5.8 billion and $6 billion, alongside an increase in its share repurchase program authorization from $500 million to $1 billion, which is expected to enhance shareholder value. This strong financial outlook and strategic moves are likely to attract increased investor interest, despite the overall market weakness.
The positive projections for revenue and earnings per share indicate a solid growth trajectory for Option Care Health, positioning it favorably in the healthcare sector and potentially boosting its market confidence.
Analyst Views on OPCH
Wall Street analysts forecast OPCH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPCH is 36.22 USD with a low forecast of 27.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.720
Low
27.00
Averages
36.22
High
40.00
Current: 34.720
Low
27.00
Averages
36.22
High
40.00
About OPCH
Option Care Health, Inc. is an independent provider of home and alternate site infusion services. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
